Scarica l'app Stockscreener
34.80
5.58%
1.84
Dopo l'orario di chiusura:
34.79
-0.010
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics, Inc. (VKTX) latest stock news and headlines - Yahoo Finance Singapore
Viking Therapeutics, Inc. (VKTX) interactive stock chart - Yahoo Finance Singapore
Viking Therapeutics, Inc. (VKTX) stock price, news, quote and history - Yahoo Finance Singapore
Where Will Viking Therapeutics Stock Be in 10 Years? - The Globe and Mail
Where Will Viking Therapeutics Stock Be in 10 Years? - The Motley Fool
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics (VKTX) stock has failed to impress since Jim Cramer expressed caution - msn.com
VKTX Stock Price, Quote & Chart | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How (VKTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today - Sahm
[ARS] Viking Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Viking Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors - MSN
43,152 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Royal Fund Management LLC - MarketBeat
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More - AOL.com
A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Enrollment Milestone Advances VK2735 Program - Sahm
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
VKTX stock jumps as retail traders pile into obesity pipeline bets - MSN
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Full VK2735 Phase 3 Enrollment Progress - Sahm
Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution - Insider Monkey
Viking Therapeutics, Inc. (VKTX) Falls Further Than the Overall Market: What Investors Should Know - Bitget
Viking Therapeutics Approaches Make-or-Break Moment as Key GLP-1 Data Looms - NAI500
Viking Therapeutics moves closer to challenging Ozempic with phase 3 trial progress - MSN
Viking Therapeutics: A Small Biotech Firm Competing in the $100B GLP-1 MarketNews and Statistics - indexbox.io
1 Reason This Biotech Stock Could Triple Before Year-End - Yahoo Finance
VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets - stocktwits.com
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion - Yahoo Finance
Viking Therapeutics Inc (VKTX) Stock Price, Quote, News & History - Benzinga
Viking Therapeutics Trial Milestone Highlights VK2735 And Valuation Gap - simplywall.st
Vanguard disaggregates holdings; reports 0 shares in Viking (VKTX) - Stock Titan
VKTX Completes Participant Recruitment for Second Advanced Clinical Trial of Obesity Medication - Bitget
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug - Yahoo Finance
Viking Therapeutics completes patient enrolment in VANQUISH-2 trial - Clinical Trials Arena
Viking Therapeutics completes enrollment in obesity drug trial By Investing.com - Investing.com Australia
Published on: 2026-03-27 10:35:11 - baoquankhu1.vn
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
VKTX.O - Reuters
Viking Therapeutics (NASDAQ:VKTX) Now Covered by Wolfe Research - MarketBeat
Morgan Stanley reiterates Viking Therapeutics stock rating on trial progress - Investing.com
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Viking Therapeutics (VKTX) Completes Enrollment for Key Clinical Trials - GuruFocus
Viking Therapeutics completes enrollment in obesity drug trial - Investing.com
Viking Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - MarketScreener
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - nasdaq.com
Is It Too Late To Revisit Viking Therapeutics (VKTX) After Its Multi Year Surge? - simplywall.st
A Stark Divide: Viking Therapeutics' Share Price Lags Far Behind Analyst Conviction - AD HOC NEWS
Meadowbrook Wealth Management LLC Invests $1.31 Million in Viking Therapeutics, Inc. $VKTX - MarketBeat
Why Viking Therapeutics, Inc. (VKTX) dipped more than broader market today - MSN
Viking Therapeutics Secures Manufacturing Might Ahead of Pivotal Data - AD HOC NEWS
Cantor Fitzgerald Initiates Coverage of Viking Therapeutics (VKTX) with Overweight Recommendation - msn.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):